Literature DB >> 31439450

DNA damage enhancement by radiotherapy-activated hafnium oxide nanoparticles improves cGAS-STING pathway activation in human colorectal cancer cells.

Julie Marill1, Naeemunnisa Mohamed Anesary1, Sébastien Paris2.   

Abstract

The cGAS-STING pathway can be activated by radiation induced DNA damage and because of its important role in anti-cancer immunity activation, methods to increase its activation in cancer cells could provide significant therapeutic benefits for patients. We explored the impact of hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy on cell death, DNA damage, and activation of the cGAS-STING pathway. We demonstrate that NBTXR3 activated by radiotherapy enhances cell destruction, DNA double strand breaks, micronuclei formation and cGAS-STING pathway activation in a human colorectal cancer model, compared to radiotherapy alone.
Copyright © 2019 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; NBTXR3; Nanoparticle; Radiotherapy; cGAS-STING

Mesh:

Substances:

Year:  2019        PMID: 31439450     DOI: 10.1016/j.radonc.2019.07.029

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  20 in total

Review 1.  Enhancing cancer immunotherapy with nanomedicine.

Authors:  Darrell J Irvine; Eric L Dane
Journal:  Nat Rev Immunol       Date:  2020-01-31       Impact factor: 53.106

2.  Molecular intervention of colon cancer and inflammation manifestation by tannin capped biocompatible controlled sized gold nanoparticles from Terminalia bellirica: A green strategy for pharmacological drug formulation based on nanotechnology principles.

Authors:  S Karthick Raja Namasivayam; Gayathri Venkatachalam; R S Arvind Bharani; J Aravind Kumar; S Sivasubramanian
Journal:  3 Biotech       Date:  2021-08-07       Impact factor: 2.893

Review 3.  Controlled-Release Nanosystems with a Dual Function of Targeted Therapy and Radiotherapy in Colorectal Cancer.

Authors:  Pedro Cruz-Nova; Alejandra Ancira-Cortez; Guillermina Ferro-Flores; Blanca Ocampo-García; Brenda Gibbens-Bandala
Journal:  Pharmaceutics       Date:  2022-05-20       Impact factor: 6.525

Review 4.  Review of clinical applications of radiation-enhancing nanoparticles.

Authors:  N Scher; S Bonvalot; C Le Tourneau; E Chajon; C Verry; J Thariat; V Calugaru
Journal:  Biotechnol Rep (Amst)       Date:  2020-10-28

Review 5.  High-Z Metal-Organic Frameworks for X-ray Radiation-Based Cancer Theranostics.

Authors:  Megan J Neufeld; Alec Lutzke; Guillem Pratx; Conroy Sun
Journal:  Chemistry       Date:  2020-12-15       Impact factor: 5.236

6.  Radiotherapy-Activated Hafnium Oxide Nanoparticles Produce Abscopal Effect in a Mouse Colorectal Cancer Model.

Authors:  Ping Zhang; Audrey Darmon; Julie Marill; Naeemunnisa Mohamed Anesary; Sébastien Paris
Journal:  Int J Nanomedicine       Date:  2020-05-29

Review 7.  Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme.

Authors:  Jinyeong Choi; Gaeun Kim; Su Bin Cho; Hyung-Jun Im
Journal:  J Nanobiotechnology       Date:  2020-09-03       Impact factor: 10.435

8.  A STING-related prognostic score predicts high-risk patients of colorectal cancer and provides insights into immunotherapy.

Authors:  Si-Yuan Chen; Siyu Chen; Wanjing Feng; Ziteng Li; Yixiao Luo; Xiaodong Zhu
Journal:  Ann Transl Med       Date:  2021-01

Review 9.  Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer.

Authors:  Kangkang Ying; Bingjun Bai; Xing Gao; Yuzi Xu; Hangxiang Wang; Binbin Xie
Journal:  Front Bioeng Biotechnol       Date:  2021-07-07

10.  Hafnium (IV) oxide obtained by atomic layer deposition (ALD) technology promotes early osteogenesis via activation of Runx2-OPN-mir21A axis while inhibits osteoclasts activity.

Authors:  A Seweryn; M Alicka; A Fal; K Kornicka-Garbowska; K Lawniczak-Jablonska; M Ozga; P Kuzmiuk; M Godlewski; K Marycz
Journal:  J Nanobiotechnology       Date:  2020-09-15       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.